Non-Cochrane · prevalence · PM42063222
Adherence to oral antineoplastic agents, an overview and meta-analysis.
Mourath David, Fohlin Helena · The oncologist · 2026 · PubMed · doi:10.1093/oncolo/oyag168
Findings
Population Adult patients treated with non-endocrine oral antineoplastic agents (traditional chemotherapy and targeted therapy)
2 findings
| Adherence measured objectively (MEMS, MPR or PDC) | None | Cumulative adherence Study durations varied (<6 months and >=6 months) · Real-world oral anticancer therapy | Pooled proportion (random-effects, logit) 0.84 [0.78, 0.89] GRADE not reported 17 studies · 7262 participants |
| Adherence measured objectively (MEMS, MPR or PDC) | None | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) Study durations varied · Real-world oral anticancer therapy | Pooled proportion (random-effects, logit) 0.71 [0.63, 0.78] GRADE not reported 20 studies · 31230 participants |
Included primary studies 25
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Jiang 2019 matched by author and year (probable) | NR | 1 other review | Cumulative adherence | not extracted yet |
| Morgan 2018 matched by author and year (probable) | NR | 1 other review | Cumulative adherence | not extracted yet |
| Anderson 2015 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Darkow 2007 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Dinan 2022 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Engel-Nitz 2023 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Feiten 2016 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Feiten 2016 Calorimeters for pulsed lasers: calibration. PMID:20165270 | 1976 | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Feral 2022 matched by author and year (probable) | NR | this review only | Cumulative adherence | not extracted yet |
| Gatwood 2022 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Guerin 2012 matched by author and year (probable) | NR | this review only | Cumulative adherence | not extracted yet |
| Hess 2017 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Jacobs 2017 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Jacobs 2019 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Komatsu 2020 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Krikorian 2019 matched by author and year (probable) | NR | this review only | Cumulative adherence | not extracted yet |
| Mallick 2013 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Melis 2023 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Middendorff 2018 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Moss 2021 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Partridge 2010 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Skrabal Ross 2022 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Spoelstra 2013 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Stokes 2017 matched by author and year (probable) | NR | this review only | Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
| Trivedi 2014 matched by author and year (probable) | NR | this review only | Cumulative adherence; Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
| Review | Shared studies | Jaccard |
|---|---|---|
| Meta-analysis of caries microbiome studies can improve upon disease prediction outcomes. (2022) | 1 | 0.03 |
| Evaluating the DMFT and dmft indices in people with epilepsy: A systematic review and meta-analysis. (2025) | 1 | 0.03 |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adult patients treated with non-endocrine oral antineoplastic agents | Adults on oral antineoplastic agents: meta-analysis cumulative 7262 patients (17 studies, 21 cohorts); lower-bound 31230 patients (20 studies, 22 cohorts) |
| Intervention | Any adherence measuring technique | MEMS, MPR or PDC adherence measurement (n=28 studies in meta-analysis); 75 original studies and 8 reviews overall |
| Comparison | Omitted (no relevant comparison) | None |
| Outcomes | Quantitative adherence outcomes | Cumulative adherence 84% (95% CI 78-89); lower-bound adherence 71% (95% CI 63-78) |
| Study designs | Clinical studies in humans; meta-analysis restricted to objective measures (MEMS, MPR, PDC) reporting cumulative or lower-bound adherence | 75 original studies (1987 to 2023) and 8 reviews; 28 studies pooled |
| Timing | Not specified | Not specified |